Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Edscharp who wrote (10171)	5/24/1999 2:00:00 PM
From: aknahow	Respond to of 17367

Edward, thanks. Interesting how almost half of todays trades are "institutional" When consideration is given to the non I Watch reported trades one could conclude that over half of todays total volume is institutional. Also 3 sets of messages for 100,000 shares. Can't remember what I used to post about before, we were told about this sight! Why? Why? Why? If a letter writer says he expects a deal to be signed (soon), with not a lot of hedging, ("expect" is a hedge word), wonder what institutional buyers of the stock know.

To: Edscharp who wrote (10171)	5/25/1999 9:06:00 AM
From: aknahow	Respond to of 17367

Edward, interesting and IMO important article in IBD 25 May. Page A 10 "Targeted" Monoclonal Antibodies Leading Newest Wave In Biotech Drugs. XOMA is not mentioned. Yet the article has important positive implications for XOMA especially due to both its' cell expression process and its' humanization process. "Rituxan and Herceptin............work because Idec and Genetech "humanized" them." "Sales of monoclonal antibody drugs should grow an average of 70% a year between 1996 and 2001, up from just 2% in 1996." I wish to point out that this growth is mainly going to come from existing products, according to the article, and won't IMO impact XOMA in a positive way. Having licensed its' cell expression process to 16 and having about a dozen others looking at it IMO puts XOMA in a very positive position with a non core product that could in time produce significant cash flow. I hope we will see progress on the humanization side as well.

To: Edscharp who wrote (10171)	5/25/1999 6:31:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

It will be interesting to see what the letter writers have to say. IMO it is a real positive to find that the target was 35 and that it was not reached. While it will take unblinding to see the results I find it hard to believe that this low number was due to the placebo working well. Have just heard that the total enrolled in the trial was 395. Overall mortality was under 9%. And we know those to be enrolled were very ill because 62 died before they could be enrolled. BTW apparently there were 1 million votes against management on 5 of the 6 propositions. Only 800,000 votes against appointing the auditor, and frankly I can understand why this one was more difficult to vote against. Thanks to all who voted against management. I hope that in the future XOMA will follow Jack Castello's example and disclose more sooner. To Gonzalez apparently the trial has been irreparably ruined by disclosure of these secret numbers!!! (395, 35, 34)<g>